Clinical TrialJun 22, 2026, 08:08 AM
Clearmind Medicine Completes Part A of CMND-100 Clinical Trial
AI Summary
Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial for CMND-100, a therapeutic candidate for Alcohol Use Disorder (AUD). All 24 participants across the four cohorts have completed treatment according to the study protocol. The company is now assessing the collected data and intends to advance to the next stage of the clinical program, involving AUD patients, assuming favorable results. This multicenter trial is being conducted under FDA oversight at leading research centers in the United States and Israel.
Key Highlights
- Completed treatment for all participants in Part A of Phase I/II clinical trial for CMND-100.
- All 24 participants across Cohorts 1 through 4 successfully completed treatment.
- CMND-100 is being evaluated for the treatment of Alcohol Use Disorder (AUD).
- Company is assessing the dataset and plans to initiate the next stage of the clinical program in AUD patients.
- Trial is multicenter, conducted under FDA oversight at sites including Yale and Johns Hopkins.
- Clearmind Medicine is a clinical-stage biotech focused on neuroplastogen-derived therapeutics.
- Company's intellectual portfolio includes 19 patent families and 32 granted patents.
Price Impact
More from CMND